Top Page
QuantumPharm, Inc.
(2228)
QuantumPharm, Inc. (2228) vs. iShares MSCI Hong Kong ETF (EWH)
QuantumPharm, Inc. Business Overview & Revenue Model
QuantumPharm, Inc. Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 102.63M | 266.43M | 174.42M | 133.35M | 62.80M | 0.00 | Gross Profit |
| 47.15M | 123.43M | 48.24M | 66.09M | 32.78M | 0.00 | EBIT |
| -392.86M | -684.21M | -722.31M | -525.31M | -299.43M | -9.84M | EBITDA |
| -388.72M | -631.38M | -1.78B | -390.37M | -2.11B | -9.84M | Net Income Common Stockholders |
| -1.24B | -1.52B | -1.91B | -1.44B | -2.14B | -36.03M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.39B | 3.10B | 2.83B | 3.47B | 3.83B | 8.44M | Total Assets |
| 4.46B | 4.35B | 4.01B | 4.32B | 4.38B | 8.44M | Total Debt |
| 163.57M | 148.76M | 11.04B | 9.45B | 7.83B | 159.05M | Net Debt |
| -1.15B | -1.02B | 10.33B | 8.88B | 4.31B | 150.62M | Total Liabilities |
| 321.07M | 362.43M | 11.25B | 9.63B | 7.99B | 219.45M | Stockholders Equity |
| 4.12B | 3.96B | -7.27B | -5.33B | -3.61B | -211.01M |
| Cash Flow | Free Cash Flow | ||||
| -331.31M | -536.79M | -698.20M | -627.83M | -417.42M | 655.00K | Operating Cash Flow |
| -299.29M | -478.68M | -567.56M | -429.10M | -253.75M | 655.00K | Investing Cash Flow |
| 48.65M | 74.09M | 735.58M | -2.76B | -70.47M | 33.00K | Financing Cash Flow |
| 828.06M | 840.00M | -25.89M | 57.99M | 2.48B | 0.00 |
QuantumPharm, Inc. Technical Analysis
QuantumPharm, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $4.90B | 18.92 | -17.01% | 7.26% | 13.61% | -24.47% | |
45 Neutral | ― | ― | 50.10% | -212.76% | |||
| $124.52B | 6.11 | 7.57% | ― | ― | |||
| $10.87B | 46.27 | 6.14% | 1.22% | ― | ― | ||
| $13.30B | 19.73 | 13.20% | 2.55% | ― | ― | ||
| $50.59B | ― | 8.44% | 4.95% | ― | ― | ||
| $4.57B | 13.22 | 14.56% | 4.43% | ― | ― |
QuantumPharm, Inc. Corporate Events
XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced that its co-founders have voluntarily extended their lock-up undertakings for another year, demonstrating their confidence in the company’s long-term value and future prospects. This extension involves a total of 591,488,405 shares, representing 14.71% of the issued share capital, and is seen as a positive signal for stakeholders, potentially stabilizing the company’s stock and reinforcing its market position.
The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced a significant acquisition involving a 90% equity interest in a target company for RMB250 million, to be fully settled in cash. This transaction is considered a discloseable transaction under the Listing Rules, as it exceeds the 5% threshold but is below 25%, thus requiring reporting and announcement. The acquisition will result in the target company becoming an indirect non-wholly owned subsidiary of XtalPi, potentially enhancing its market position and operational capabilities.
XtalPi Holdings Limited, a company incorporated in the Cayman Islands, held its Annual General Meeting on April 29, 2025, where all proposed resolutions were passed with significant majority support. Key resolutions included the re-election of directors, re-appointment of auditors, and granting mandates for share allotment and repurchase, reflecting strong shareholder confidence and strategic alignment for future growth.
XtalPi Holdings Limited has announced its upcoming Annual General Meeting (AGM) scheduled for April 29, 2025, in Shenzhen, China. The meeting will address several key resolutions, including the re-election of directors, the re-appointment of PricewaterhouseCoopers as the company’s auditor, and a proposal to authorize the board to issue additional shares. These resolutions are aimed at strengthening the company’s governance and operational capabilities, potentially impacting its market position and stakeholder interests.
XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced that it has achieved the revenue threshold required to be classified as a Commercial Company under the Hong Kong Stock Exchange’s Listing Rules. As a result, the Stock Exchange has approved the removal of its designation as a Pre-Commercial Company, marking a significant milestone in its business development. This change in status reflects the company’s growth and positions it more favorably within the industry, potentially impacting its stakeholders positively.
XtalPi Holdings Limited announced its annual results for the year ended December 31, 2024, reporting a 52.8% increase in revenue to RMB266.4 million and a narrowed adjusted net loss by 12.5% to RMB456.8 million. The company has reached the Commercial Company revenue threshold ahead of schedule, indicating a steady progression towards large-scale development. XtalPi’s implementation of AI tools and high-efficiency strategies has reduced its monthly average cash burn by 22.6%. The company is pioneering a shift in R&D paradigms with its ‘AI + Robotics’ framework, which enhances drug and materials development through advanced AI models and high-throughput experimentation, potentially disrupting various industries.
XtalPi Holdings Limited has announced a strategic cooperation agreement between its subsidiary, Shenzhen XtalPi Technology, and the SME Development Promotion Center of the Ministry of Industry and Information Technology in China. This collaboration aims to integrate AI and robotics technologies with traditional industries to foster innovation and economic development. The partnership will leverage Shenzhen XtalPi Technology’s AI models and the Center’s extensive service network to provide sustainable solutions for SMEs, enhance competitiveness, and promote the intelligent transformation of industries such as biomedicine, chemical new materials, and consumer goods.
XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced that its board of directors will convene on March 28, 2025, to discuss and approve the annual financial results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend and address other business matters, potentially impacting the company’s financial strategy and shareholder returns.